Tag:
Ampyra
Latest Headlines
Latest Headlines
MS drugs get yeas, nays and price increases
Lots of news about the multiple sclerosis market today. Two companies raised prices, Novartis received good Gilenya news, while Merck KGaA and Biogen Idec/Acorda Therapeutics suffered setbacks
Elan announces launch of extended release Ampyra in U.S.
Following its approval earlier this year, Elan Drug Technologies has announced the launch of Ampyra (dalfampridine) by Acorda Therapeutics in the U.S. as a treatment to improve walking in patients
INCORRECT: Acorda deals MS med direct to patients
Editor's Note: Contrary to the Chicago Tribune article this piece was based on, Acorda has informed FiercePharma that the company is not selling directly to patients after all, but through specialty
Acorda MS drug approval sparks buyout buzz
Late Friday afternoon regulators at the FDA approved Acorda's multiple sclerosis drug Ampyra based on data demonstrating that patients taking dalfampridine were able to walk faster than a control
FDA approves Acorda's new MS drug
The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with multiple sclerosis. In clinical trials, patients treated
